Tempest Therapeutics (NASDAQ:TPST) Trading Down 1.6% – Here’s Why

Tempest Therapeutics, Inc. (NASDAQ:TPST)’s share price dropped 1.6% during mid-day trading on Thursday . The company traded as low as $1.24 and last traded at $1.25. Approximately 41,415 shares traded hands during trading, a decline of 65% from the average daily volume of 118,351 shares. The stock had previously closed at $1.27.

Analyst Ratings Changes

A number of equities research analysts recently commented on TPST shares. Wall Street Zen downgraded shares of Tempest Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, May 16th. Zacks Research cut Tempest Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Thursday, May 14th. One research analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Reduce”.

Tempest Therapeutics Stock Performance

The company has a market capitalization of $18.51 million, a PE ratio of -0.21 and a beta of -1.85. The firm’s 50-day simple moving average is $1.75 and its 200 day simple moving average is $2.32.

Tempest Therapeutics (NASDAQ:TPST) last announced its quarterly earnings results on Thursday, May 14th. The company reported ($2.53) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.28) by ($2.25). As a group, equities analysts anticipate that Tempest Therapeutics, Inc. will post -1.34 earnings per share for the current year.

Insider Activity

In related news, CEO Matthew Angel purchased 231,482 shares of Tempest Therapeutics stock in a transaction dated Tuesday, March 24th. The stock was bought at an average cost of $2.16 per share, for a total transaction of $500,001.12. Following the transaction, the chief executive officer owned 231,482 shares in the company, valued at approximately $500,001.12. The trade was a ∞ increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Insiders own 6.28% of the company’s stock.

Institutional Investors Weigh In On Tempest Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the company. Dimensional Fund Advisors LP purchased a new position in Tempest Therapeutics in the 4th quarter valued at approximately $33,000. Vanguard Group Inc. grew its holdings in Tempest Therapeutics by 20.8% in the third quarter. Vanguard Group Inc. now owns 162,560 shares of the company’s stock valued at $1,671,000 after purchasing an additional 27,952 shares during the last quarter. Finally, Sabby Management LLC acquired a new stake in Tempest Therapeutics in the fourth quarter valued at $513,000. Institutional investors and hedge funds own 22.52% of the company’s stock.

About Tempest Therapeutics

Tempest Therapeutics is a clinical‐stage biopharmaceutical company focused on the discovery and development of small molecule therapies for cancer and immune‐mediated diseases. Leveraging a proprietary drug discovery platform, Tempest advances programs designed to modulate tumor metabolism and enhance antitumor immunity. Its pipeline includes oral, selective inhibitors targeting pathways such as peroxisome proliferator‐activated receptor alpha (PPARα) and salt‐inducible kinase (SIK), with potential applications across solid tumors and hematologic malignancies.

The company’s lead candidate, TPST-1120, is a first‐in‐class PPARα antagonist designed to reprogram the tumor microenvironment by disrupting fatty acid oxidation in immune and cancer cells.